The multidisciplinary breast cancer care team: Promoting better care;Het multidisciplinair mammateam: Bevordering van goede zorg

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 35, 2005, Pages 1929-1931

  Van Nes, J G H ^a   Van De Velde, C J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER STAGING; CANCER THERAPY; DOCTOR PATIENT RELATION; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH PROMOTION; HUMAN; MEDICAL SPECIALIST; NURSE; PATIENT CARE; PREDICTION; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; COMPREHENSIVE HEALTH CARE; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NETHERLANDS; PATIENT CARE TEAM;

EID: 24044460104     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Siesling S, Poll-Franse LV van de, Jobsen JJ, Repelaer van Driel OJ, Voogd AC. Trends en variaties in mammasparende operaties in Zuidoost en Oost-Nederland in de periode 1990-2002. Ned Tijdschr Geneeskd 2005;149:1941-6.
3. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-16.
4. Clark GM. Prognostic and predictive factors for breast cancer. Breast Cancer 1995;2:79-89.
5. International Union Against Cancer (UICC). TNM classification of malignant tumours. Genève: UICC; 1968.
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
7. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
8. Klijn JGM, Vries EGE de. De waarde van genexpressieprofielen vast-gesteld met microarrays voor het individualiseren van adjuvante therapie bij patiënten na chirurgische behandeling wegens mammacarcinoom. Ned Tijdschr Geneeskd 2005;149:618-22.
9. Veer LJ van't, Rodenhuis S, Vijver MJ van de. Prognostische betekenis van het genexpressieprofiel van mammatumoren, bepaald met DNA-microarrays. Ned Tijdschr Geneeskd 2005;149:638-46.
10. Nold RJ, Beamer RL, Helmer SD, McBoyle MF. Factors influencing a woman's choice to undergo breast-conserving surgery versus modified radical mastectomy. Am J Surg 2000;180:413-8.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
12. Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995;345:1265-70.
13. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 2001;91:1231-7.
14. Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg 1998;186:269-74.